Arturo LoAIza-Bonilla, Systemwide Chief of Hematology and Oncology at St. Luke’s University Health Network, and Co-Founder and Chief Medical AI Officer (CMAIO) of Massive Bio, shared a post on LinkedIn:
“Just published: American Society of Clinical Oncology (ASCO)’s latest deep dive on AI in oncology and the principles that must guide its responsible use.
This piece captures a pivotal moment for our field. AI is accelerating rapidly, but its true value emerges only when it is transparent, equitable, clinically grounded, and anchored in human judgment and patient well-being. ASCO’s leadership—through its policy frameworks, its stance on AI in prior authorization, and the launch of tools like the ASCO Guidelines Assistant—is setting essential guardrails for how we integrate AI into cancer care.
What I appreciate most is the clarity of the message:
- AI will not replace oncologists. But oncologists—and care teams—who understand and shape AI will deliver better, faster, more equitable care.
- At ASCO25 we saw real momentum, from guideline innovation to hands-on exploration of new capabilities. I was grateful to contribute to this dialogue on the ASCO Daily News Podcast, where we discussed responsible AI integration across clinical workflows, trials, and multimodal discovery.
- As AI becomes a general-purpose technology transforming healthcare, our responsibility is to ensure it strengthens clinical judgment, expands access, reduces burden, and gives clinicians back the time to focus on what cannot be automated: empathy, partnership, and the human connection at the center of cancer care.
This is the moment to lead—and to shape the future of oncology with purpose and care.”
More posts featuring Arturo LoAIza-Bonilla.